Copertina

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	David Tornai, Maria Papp
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
di: David Tornai, et al.
Pubblicazione: (2026)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
di: David Tornai, et al.
Pubblicazione: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
di: Bingqiong Wang, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
di: Takao Miwa, et al.
Pubblicazione: (2026)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
di: Charlotte Mouliade, et al.
Pubblicazione: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
di: David Mehdi Asgher Niazi, et al.
Pubblicazione: (2026)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
di: Amy Sangam, et al.
Pubblicazione: (2024)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
di: Cristina Rubín de Célix, et al.
Pubblicazione: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
di: Ellen Werner, et al.
Pubblicazione: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
di: Mohammad Shehab, et al.
Pubblicazione: (2025)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
di: Erik Lundqvist, et al.
Pubblicazione: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
di: Jiong Yu, et al.
Pubblicazione: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
di: María Chaparro, et al.
Pubblicazione: (2024)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
di: Michelle Spaan, et al.
Pubblicazione: (2026)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
di: Stefano Siboni, et al.
Pubblicazione: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
di: Tanat Saeoui, et al.
Pubblicazione: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
di: Eric Lawitz, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2025)